Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
04/08/2025
Coal and coke futures main contract intraday decline expanded to 4%.
Latest
1 m ago
Guotai Haitong: The mower robot track welcomes the "singular" moment, recommends Ninth Company - WD, etc.
2 m ago
Guosen Securities: RWA Development Catalyzes Brokerage Sector Market, Follow-up Industry Still Has Double Potential
2 m ago
China CITIC International released a research report stating that WuXi AppTec (02359) had a strong performance in the first half of the year with robust growth in revenue and net profit. The profit margin expanded, and the TIDES business performed exceptionally well. At the same time, the resilience of the chemical business helped offset the weakness in the clinical CRO and testing business. Management raised their revenue guidance for 2025 to 42.5 billion to 43.5 billion yuan, with a 13% to 17% growth in continued operating business. Capital expenditure will remain at 7 billion to 8 billion yuan. China CITIC International raised their profit forecast for WuXi AppTec for the next two years by 15% and 22%, and raised the target price from 81 Hong Kong dollars to 122 Hong Kong dollars, maintaining a "buy" rating.
2 m ago
BOCI Securities: Maintains "Buy" rating on Wuxi Biologics, with target price raised to 122 Hong Kong dollars.
2 m ago
Hong Kong stocks surged | China Ru Yi (00136.HK) fell more than 3% in the morning, planning to discount approximately 4.46% of the total issued 1.3 billion subscribed shares to raise funds for strategic investments and more.
See all latest